Article History
First Online: 18 March 2019
Compliance with Ethical Standards
:
: A. Haberland, K. Wenzel, and J. Müller are employed by Berlin Cures. A. Haberland and J. Müller are shareholders of the Berlin Cures Holding AG. A. Haberland is an inventor of BC 007, and A. Haberland and K. Wenzel are inventors of the BC 007s TLR9 inhibition. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject or materials discussed in the manuscript apart from those which are disclosed.